- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05834803
Efectos de la angioplastia renal transluminal percutánea de la estenosis de la arteria renal aterosclerótica en pacientes de alto riesgo. (DAN-PTRAII)
Efectos de la angioplastia renal transluminal percutánea de la estenosis aterosclerótica de la arteria renal en pacientes de alto riesgo: un estudio danés nacional aleatorizado controlado con simulación.
The goal of this clinical trial is to investigate whether percutaneous transluminal renal angioplasty (PTRA) with stent placement of atherosclerotic renal artery stenosis is beneficial in high-risk patients selected according to the criteria used in the DAN-PTRAI study. The main questions the trial aims to answer are whether renal artery stenting in addition to optimal medical therapy, compared with a sham procedure and optimal medical therapy, has beneficial effects on:
- Blood pressure (primary outcome: 24-hour ambulatory systolic blood pressure at 6 months)
- Kidney function
- Hospitalizations for heart failure
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Even with optimal medical care, patients with renovascular disease have a very high risk of cardiovascular events and an expected poor outcome. One treatment option of atherosclerotic renal artery stenosis is percutaneous transluminal renal angioplasty with stent placement. Renal artery stenting is, however, still a subject of debate as randomized trials have failed to show a benefit of this compared with optimal medical treatment alone. Following the results of the large CORAL trial in 2014, we established the national prospective DAN-PTRAI study using strict and well-defined criteria to select patients for renal artery stenting. In this study, we observed a reduction in blood pressure, an improved kidney function, and a decrease in new hospital admissions due to heart failure after renal artery stenting.
The DAN-PTRAII study is a nationwide randomized, sham-controlled clinical trial in patients with severe renovascular disease due to atherosclerotic renal artery stenosis. Only patients who fulfill the inclusion criteria on optimal medical treatment can enter the study and only the operator and the interventional team will know whether the patients receive renal artery stenting or sham treatment. Participants will be followed closely for 6 months after the treatment to evaluate the effects of renal artery stenting compared with a sham procedure, both in addition to optimal medical therapy, on blood pressure, kidney function, and hospitalizations for heart failure.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Sebastian Nielsen, MD
- Número de teléfono: +45 23100484
- Correo electrónico: sebane@rm.dk
Copia de seguridad de contactos de estudio
- Nombre: Mark Reinhard, MD, PhD
- Número de teléfono: +45 40460321
- Correo electrónico: markrein@rm.dk
Ubicaciones de estudio
-
-
-
Aarhus N, Dinamarca, 8200
- Reclutamiento
- Aarhus University Hospital
-
Contacto:
- Sebastian Nielsen, MD
- Correo electrónico: sebane@rm.dk
-
Contacto:
- Mark Reinhard, MD, PhD
- Correo electrónico: markrein@rm.dk
-
Copenhagen, Dinamarca, 2100
- Reclutamiento
- Rigshospitalet
-
Contacto:
- Jonas P Eiberg, MD, PhD
- Correo electrónico: jonas.peter.eiberg@regionh.dk
-
Odense C, Dinamarca, 5000
- Reclutamiento
- Odense University Hospital
-
Contacto:
- Michael D Schultz, MD
- Correo electrónico: michael.dyrehauge.schultz@rsyd.dk
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
One or more severe atherosclerotic renal artery stenoses defined as a stenosis ≥70% by catheter-based angiography.
-
In addition, at least one of the following high-risk clinical syndromes:
- Resistant hypertension with average 24-hour ambulatory systolic blood pressure ≥150 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.
- Rapidly declining kidney function with a reduction in estimated GFR of >5 mL/min per 1.73m2 per year and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.
- Hospital admissions with acute decompensated heart failure (≥2 hospitalizations for heart failure or ≥1 hospitalization for sudden, "flash" pulmonary edema) with no obvious explanations such as nonadherence, left ventricular ejection fraction <40%, or valvular heart disease and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.
All 24-hour ambulatory blood pressure measurements are performed after nurse-administered medication.
Exclusion Criteria:
- Unable to provide informed consent.
- Treatment-resistant heart failure episodes presumed caused by renovascular disease.
- Rapidly declining kidney function/acute kidney failure approaching the need for dialysis presumed caused by renovascular disease.
- Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis known to be present prior to randomization.
- Pregnancy or unknown pregnancy status in female of childbearing potential.
- Kidney size <7 cm (pole to pole length) supplied by target vessel.
- Previous kidney transplant.
- Previous PTRA with stent placement.
- Presence of a renal artery stenosis not amenable for treatment with a stent.
- Intolerance to any antithrombotic treatment.
Patients who are not eligible for randomization but treated with renal artery stenting outside the protocol are followed according to the DAN-PTRAII protocol in order to account for all PTRA treatments performed in Denmark in the study period.
Patients treated with renal artery stenting without randomization in the study period include patients with:
-
Treatment-resistant heart failure episodes presumed caused by renovascular disease.
-
Rapidly declining kidney function/acute kidney failure approaching the need for dialysis presumed caused by renovascular disease.
-
At least one of the listed high-risk clinical syndromes AND one or more significant atherosclerotic renal artery stenoses defined as a stenosis of 50-69% by catheter-based angiography with:
- a mean translesional gradient of ≥10 mmHg, or
- a systolic translesional gradient of ≥20 mmHg, or
- a renal fractional flow reserve (Pd/Pa) of ≤0.80
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Renal artery stenting
Percutaneous transluminal renal angioplasty with stent placement |
Catheter-based angiography performed in accordance with the study protocol. Measurement of translesional pressure gradients performed in accordance with the study protocol. Optimal medical therapy, including maximally tolerated renin-angiotensin system blockade with either an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker. Renal artery stenting performed in accordance with the study protocol. |
|
Comparador falso: Sham procedure
Sham procedure |
Catheter-based angiography performed in accordance with the study protocol. Measurement of translesional pressure gradients performed in accordance with the study protocol. Optimal medical therapy, including maximally tolerated renin-angiotensin system blockade with either an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker. Sham procedure performed in accordance with the study protocol. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in 24-hour ambulatory systolic blood pressure
Periodo de tiempo: Baseline and 6 months
|
Defined as the between-group difference in the change in 24-hour ambulatory systolic blood pressure from baseline to 6 months. |
Baseline and 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in estimated glomerular filtration rate (eGFR)
Periodo de tiempo: Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 4.5 months, and 6 months
|
Defined as the between-group difference in the change in estimated glomerular filtration rate (eGFR) from baseline to 6 months. |
Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 4.5 months, and 6 months
|
|
Change in urine albumin-to-creatinine ratio (UACR)
Periodo de tiempo: Baseline, 3 months, and 6 months
|
Defined as the between-group difference in the change in urine albumin-to-creatinine ratio from baseline to 3 and 6 months. |
Baseline, 3 months, and 6 months
|
|
Change in attended automated office systolic blood pressure
Periodo de tiempo: Baseline, 3 months, and 6 months
|
Defined as the between-group difference in the change in attended automated office systolic blood pressure from baseline to 3 and 6 months. |
Baseline, 3 months, and 6 months
|
|
Change in unattended automated office systolic blood pressure
Periodo de tiempo: Baseline, 3 months, and 6 months
|
Defined as the between-group difference in the change in unattended automated office systolic blood pressure from baseline to 3 and 6 months. |
Baseline, 3 months, and 6 months
|
|
Change in defined daily dose (DDD) of antihypertensive medications
Periodo de tiempo: Baseline, 3 months, and 6 months
|
Defined as the between-group difference in the change in defined daily dose (DDD) of antihypertensive medications from baseline to 3 and 6 months. |
Baseline, 3 months, and 6 months
|
|
Change in the number of antihypertensive medications
Periodo de tiempo: Baseline, 3 months, and 6 months
|
Defined as the between-group difference in the change in the number of antihypertensive medications from baseline to 3 and 6 months. |
Baseline, 3 months, and 6 months
|
|
Change in 24-hour ambulatory systolic blood pressure (corrected for changes in antihypertensive medication)
Periodo de tiempo: Baseline, 3 months, and 6 months
|
Defined as the between-group difference in the change in 24-hour ambulatory systolic blood pressure from baseline to 3 and 6 months, corrected for changes in antihypertensive medication burden (1 DDD = 5 mmHg). |
Baseline, 3 months, and 6 months
|
|
Number of participants with cardiovascular or kidney outcomes
Periodo de tiempo: From baseline to 6 months
|
Between-group comparison of the number of participants with clinical events from baseline to 6 months. Clinical events are defined using the same criteria as in the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial, except for progressive renal insufficiency (defined in CORAL as a reduction from baseline of 30% or more in estimated GFR). Clinical events included in the composite endpoint from baseline to 6-month follow-up are:
Only the first event per participant is included in the composite. |
From baseline to 6 months
|
|
Number of deaths from any cause
Periodo de tiempo: From baseline to 6 months
|
Between-group comparison of the number of participants with death from any cause from baseline to 6 months. |
From baseline to 6 months
|
|
Change in health status on 12-item Short Form Health Survey (SF-12)
Periodo de tiempo: Baseline, 3 months, and 6 months
|
Defined as the between-group difference in the change in 12-item Short Form Health Survey (SF-12) scores from baseline to 3 and 6 months. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning. |
Baseline, 3 months, and 6 months
|
|
Number of serious adverse events (SAEs) during follow-up and procedure-related and postoperative adverse events within 30 days after the procedure
Periodo de tiempo: From baseline to 6 months (SAEs); from baseline to 30 days (procedure-related and postoperative adverse events)
|
All SAEs occurring from baseline to 6 months, as well as procedure-related adverse events (≤24 hours) and postoperative adverse events (>24 hours) occurring within 30 days after the procedure, will be systematically recorded. Events include, but are not limited to:
|
From baseline to 6 months (SAEs); from baseline to 30 days (procedure-related and postoperative adverse events)
|
|
Change in intrarenal resistive index
Periodo de tiempo: Baseline and 6 months
|
Defined as the between-group difference in the change in intrarenal resistive index (unitless) of the affected kidney from baseline to 6 months, measured by Doppler ultrasound. Additional renal ultrasound and Doppler parameters (kidney length, peak systolic velocity, acceleration time, renal-renal ratio, and pulsatility index) will be assessed at baseline and 6 months and compared between groups. In exploratory analyses, the association between baseline intrarenal resistive index (≥0.80 vs <0.80) and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated, and the diagnostic accuracy (sensitivity and specificity) of baseline Doppler ultrasound for identifying hemodynamically significant renal artery stenosis will be assessed using invasive pressure measurement as the reference standard. |
Baseline and 6 months
|
|
Change in left ventricular mass index
Periodo de tiempo: Baseline and 6 months
|
Defined as the between-group difference in the change in left ventricular mass index (g/m²) from baseline to 6 months, assessed by transthoracic echocardiography. Additional transthoracic echocardiographic parameters of cardiac systolic and diastolic function and cardiac chamber dimensions and volumes will be assessed at baseline and 6 months and compared between groups. |
Baseline and 6 months
|
|
Change in split renal function of the affected kidney
Periodo de tiempo: Baseline and 6 months
|
Defined as the between-group difference in the change in split renal function (%) of the affected kidney from baseline to 6 months, assessed by renography. The change in renogram configuration (renogram grade) of the affected kidney from baseline to 6 months will be compared between groups as the proportion of participants with improvement in renogram grade. In exploratory analyses, the diagnostic accuracy (sensitivity and specificity) of baseline renography for identifying hemodynamically significant renal artery stenosis will be assessed using invasive pressure measurement as the reference standard, and the association between baseline renography with intermediate/high probability of renovascular hypertension and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated. |
Baseline and 6 months
|
|
Translesional pressure ratio (Pd/Pa) across renal artery stenoses
Periodo de tiempo: Baseline and 6 months
|
Defined as the distal-to-aortic pressure ratio (Pd/Pa, unitless) across the target renal artery stenosis, measured by intra-arterial pressure assessment during the endovascular procedure. Systolic, diastolic, mean, and pulse pressure gradients (mmHg) across the target renal artery stenosis will be measured invasively during the procedure. In exploratory analyses, the association between baseline Pd/Pa and mean and systolic translesional pressure gradients and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated, and whether the effect of PTRA differs according to baseline Pd/Pa will be explored. |
Baseline and 6 months
|
|
Agreement between CFD-derived and invasively measured translesional pressure ratio (Pd/Pa)
Periodo de tiempo: Baseline and 6 months
|
Defined as the mean difference (Bland-Altman bias, unitless) between Pd/Pa derived non-invasively from CT angiography using computational fluid dynamics (CFD) and Pd/Pa measured invasively during the endovascular procedure. Agreement between CFD-derived and invasively measured mean and systolic translesional pressure gradients will be assessed correspondingly. In exploratory analyses, the association between CFD-derived Pd/Pa and mean and systolic translesional pressure gradients and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated. |
Baseline and 6 months
|
|
Change in plasma renin
Periodo de tiempo: Baseline, 3 months, and 6 months
|
Defined as the between-group difference in the change in plasma renin concentration (mIU/L) from baseline to 3 and 6 months. In exploratory analyses, the association between baseline plasma renin and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated. |
Baseline, 3 months, and 6 months
|
|
Change in plasma aldosterone
Periodo de tiempo: Baseline, 3 months, and 6 months
|
Defined as the between-group difference in the change in plasma aldosterone concentration (pmol/L) from baseline to 3 and 6 months. In exploratory analyses, the association between baseline plasma aldosterone and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months will be evaluated. |
Baseline, 3 months, and 6 months
|
|
Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Periodo de tiempo: Baseline, 3 months, and 6 months
|
Defined as the between-group difference in the change in plasma NT-proBNP concentration (ng/L) from baseline to 3 and 6 months. In exploratory analyses, the association between changes in echocardiographic parameters, including left ventricular mass index, and the change in NT-proBNP from baseline to 6 months will be evaluated to assess whether changes in NT-proBNP reflect changes in cardiac structure and function. |
Baseline, 3 months, and 6 months
|
|
Proteomic profile in blood and on the angioplasty balloon
Periodo de tiempo: Baseline and 6 months
|
Defined as the proteomic profile in blood and in material retrieved from the angioplasty balloon after dilation during PTRA. In exploratory analyses, the association between the proteomic profile and the change in 24-hour ambulatory systolic blood pressure and eGFR from baseline to 6 months, and the need for reintervention due to restenosis, will be evaluated. Proteomic analyses will be described in a separate analysis plan. |
Baseline and 6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Mark Reinhard, MD, PhD, Aarhus University Hospital
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades cardíacas
- Enfermedades arteriales oclusivas
- Hipertensión
- Hipertensión Renal
- Insuficiencia cardiaca
- Obstrucción de la arteria renal
- Hipertensión Renovascular
- ácido salicilhidroxámico
Otros números de identificación del estudio
- DAN-PTRAII
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .